Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that through friendly consultation, it has reached a termination agreement with Shanghai Huizheng. Shanghai Huizheng has stopped holding the promotion right of LipoDex in mainland China and will no longer continue to fulfill the promotion agreement. After offsetting the payment obligations of both parties, the company will pay Shanghai Huizheng approximately 74.84 million yuan.
復旦張江(01349.HK)終止里葆多內地推廣服務協議
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) terminates agreement on promotion services in mainland China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.